

**ATTORNEY'S DOCKET CS-120
PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:)	Group Art Unit: 1642
)	
TALOR)	Examiner: Gary B. Nickol
)	
Serial No. 10/611,914)	
)	
Filed: July 03, 2003)	

For: A METHOD OF PRE-SENSITIZING CANCER PRIOR TO TREATMENT WITH RADIATION AND/OR CHEMOTHERAPY AND A NOVEL CYTOKINE MIXTURE

Appendix A

Please amend the claims according to the July 30, 2003, revision to 37 C.F.R. § 1.121 concerning a manner for making amendments to the specification.

Please amend paragraph 15 as shown in the replacement paragraph as follows:

In other specific applications, the serum-free and mitogen-free cytokine preparation or pharmaceutical composition has further different cytokines and other small biologically active molecules in Multikine® wherein the ratio of each of the small biologically active molecules to ~~IL-2~~ IL-2 is as follows: IL-3 to ~~IL-2~~ IL-2 in a ratio range of 0.38 - 0.68, preferably at

0.53 \pm 0.15, IL-6 to ~~IL-2~~ IL-2 in a ratio range of 37.2 - 53.8, preferably at 46 \pm 5.9, IL-8 to ~~IL-2~~ IL-2 in a ratio range of 261 - 561.5, preferably at 41 411 \pm 10.6, IL-1 α to ~~IL-2~~ IL-2 in a ratio range of 0.56 - 0.94, preferably at 0.75 \pm 0.19, IL-10 to ~~IL-2~~ IL-2 in a ratio range of ~~2.87~~ 2.82 - 3.22, preferably at 3.0 \pm 0.18, IL-16 to ~~IL-2~~ IL-2 in a ratio range of ~~1.24~~ 1.16 - 2.84, preferably at 1.84 \pm 0.68, G-CSF to ~~IL-2~~ IL-2 in a ratio range of 2.16 - 3.78, preferably at 2.97 \pm 0.81, TNF- β to ~~IL-2~~ IL-2 in a ratio range of ~~1.18~~ 1.17 - 2.43, preferably at 1.8 \pm 0.63, MIP-1 α to ~~IL-2~~ IL-2 in a ratio range of ~~16.78~~ 15.7 - 37.16, preferably at 22.7 \pm 7.0, MIP-1 β to ~~IL-2~~ IL-2 in a ratio range of ~~19.2 - 26.4~~ 17.1 - 28.5, preferably at 22.8 \pm 5.7, a RANTES to ~~IL-2~~ IL-2 in a ratio range of 2.3 - 2.7, preferably at 2.5 \pm 0.13, a EGF to ~~IL-2~~ IL-2 in a ratio range of ~~0.27 - 0.28~~ 0.267 - 0.283, preferably at 0.275 \pm 0.008, PGE₂ to ~~IL-2~~ IL-2 in a ratio range of ~~3.68~~ 3.63 - 5.42, preferably at 4.5 \pm 0.87 and TxB₂ to ~~IL-2~~ IL-2 in a ratio range of ~~23.5 - 25.1~~ 23.47 - 25.13 , preferably at 24.3 \pm 0.83.

Please amend paragraph 26 as shown in the replacement paragraph as follows:

The remainder of the different cytokines and other small biologically active molecules in Multikine® are also present within each preparation of the small biologically active molecules to ~~IL-2~~ IL-2 as follows: IL-3 to ~~IL-2~~ IL-2 in a ratio range of 0.38 - 0.68, preferably at 0.53 +/-0.15, IL-6 to ~~IL-2~~ IL-2 in a ratio range of 37.2 - 53.8, preferably at 46 +/-5.9, IL-8 to ~~IL-2~~ IL-2 in a ratio range of 261 - 561.5, preferably at ~~41~~ 411 +/-10.6, IL-1 α to ~~IL-2~~ IL-2 in a ratio range of 0.56 - 0.94, preferably at 0.75 +/-0.19, IL-10 to ~~IL-2~~ IL-2 in a ratio range of ~~2.87~~ 2.82 - 3.22, preferably at 3.0 +/-0.18, IL-16 to ~~IL-2~~ IL-2 in a ratio range of ~~1.24~~ 1.16 - 2.84, preferably at 1.84 +/-0.68, G-CSF to ~~IL-2~~ IL-2 in a ratio range of 2.16 - 3.78, preferably at 2.97 +/-0.81, TNF- β to ~~IL-2~~ IL-2 in a ratio range of ~~1.18~~ 1.17 - 2.43, preferably at 1.8 +/-0.63, MIP-1 α to ~~IL-2~~ IL-2 in a ratio range of ~~16.78~~ 15.7 - 37.16, preferably at 22.7 +/-7.0, MIP-1 β to ~~IL-2~~ IL-2 in a ratio range of ~~19.2~~ 17.1 - 28.5, preferably at 22.8 +/-5.7, a RANTES to ~~IL-2~~

IL-2 in a ratio range of 2.3 - 2.7, preferably at 2.5 +/-0.13,
a EGF to ~~I1-2~~ IL-2 in a ratio range of ~~0.27~~ ~~0.28~~ 0.267 -
0.283, preferably at 0.275 +/-0.008, PGE₂ to ~~I1-2~~ IL-2 in a
ratio range of ~~3.68~~ 3.63 - 5.42, preferably at 4.5 +/-0.87 and
TxB₂ to ~~I1-2~~ IL-2 in a ratio range of ~~23.5~~ ~~25.1~~ 23.47 - 25.13
, preferably at 24.3 +/-0.83.